CollaGenex Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate Incyclinide (COL-3) for the Treatment of Acne.

Business Wire › September 26, 2005

Linked as:

Extract

CollaGenex Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate Incyclinide (COL-3) for the Treatment of Acne.

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced that it has initiated a Phase 2, double-blinded, placebo-controlled, dose-finding clinical trial to evaluate the safety and efficacy of its novel compound, incyclinide (formerly known as COL-3), for the treat...

See the full content of this document